4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

2025-09-30 05:08:14 ET

4D Molecular Therapeutics (FDMT) seems an attractive buy in late 2025, especially for long-term investors with a high-risk appetite and who can tolerate short-term volatility. With shares priced at $8.35 (as of September 29) and a market capitalization of around $389.97 million, the company trades below its cash balance of $417 million . This disconnect highlights the growth potential of this stock, as investors are getting a company with a high-value research pipeline and robust business momentum for hardly any cost. Hence, I rate this stock as a high-conviction but speculative buy....

Read the full article on Seeking Alpha

For further details see: